Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASIA-ICH: Anti-Streptococcus mutans IgY for cerebral small vessel disease
jRCTs051240301Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- May 2025
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Single-arm trial of anti-Streptococcus mutans IgY antibody in cerebral microbleed (CMBs), Cerebral Small Vessel Disease (CSVD) and vascular cognitive disorder (VCD), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Newly developed cerebral microbleeds at 52 weeks. Started May 2025; status: recruiting.
02
Drugs
anti-Streptococcus mutans IgY antibody
03
Conditions
cerebral microbleed (CMBs)Cerebral Small Vessel Disease (CSVD)vascular cognitive disorder (VCD)
Beyond the preview
Go deeper on jRCTs051240301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051240301.